Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Morgan Stanley Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Tipranks - Tipranks - Thu Apr 16, 6:31AM CDT

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $612.00.

Claim 30% Off TipRanks

According to TipRanks, Flynn is a 5-star analyst with an average return of 9.0% and a 54.42% success rate. Flynn covers the Healthcare sector, focusing on stocks such as BioNTech SE, Johnson & Johnson, and Vertex Pharmaceuticals.

In addition to Morgan Stanley, Vertex Pharmaceuticals also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued today. However, on April 2, Erste Group maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).

See the top stocks recommended by analysts >>

Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.23 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $2.91 billion and had a net profit of $913 million

Read More on VRTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).